Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;131(9):1473-1479.
doi: 10.1038/s41416-024-02851-z. Epub 2024 Sep 18.

Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank

Affiliations

Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank

Xin Yang et al. Br J Cancer. 2024 Nov.

Abstract

Background: The clinical validity of the multifactorial BOADICEA model for epithelial tubo-ovarian cancer (EOC) risk prediction has not been assessed in a large sample size or over a longer term.

Methods: We evaluated the model discrimination and calibration in the UK Biobank cohort comprising 199,429 women (733 incident EOCs) of European ancestry without previous cancer history. We predicted 10-year EOC risk incorporating data on questionnaire-based risk factors (QRFs), family history, a 36-SNP polygenic risk score and pathogenic variants (PV) in six EOC susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2).

Results: Discriminative ability was maximised under the multifactorial model that included all risk factors (AUC = 0.68, 95% CI: 0.66-0.70). This model was well calibrated in deciles of predicted risk with calibration slope=0.99 (95% CI: 0.98-1.01). Discriminative ability was similar in women younger or older than 60 years. The AUC was higher when analyses were restricted to PV carriers (0.76, 95% CI: 0.69-0.82). Using relative risk (RR) thresholds, the full model classified 97.7%, 1.7%, 0.4% and 0.2% women in the RR < 2.0, 2.0 ≤ RR < 2.9, 2.9 ≤ RR < 6.0 and RR ≥ 6.0 categories, respectively, identifying 9.1 of incident EOC among those with RR ≥ 2.0.

Discussion: BOADICEA, implemented in CanRisk ( www.canrisk.org ), provides valid 10-year EOC risks and can facilitate clinical decision-making in EOC risk management.

PubMed Disclaimer

Conflict of interest statement

ACA and DFE are named creators of the BOADICEA model, which has been licensed by Cambridge Enterprise (University of Cambridge). The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Observed and predicted 10-year EOC risks under individual or different combinations of risk factors*.
*Women were grouped into deciles based on their predicted risks. Each dot represents the mean observed and predicted risk in the decile and the error bar represents the 95% confidence intervals. The dashed line is the reference line with slope equals to 1, on which the observed risk equals to the predicted risk. When the confidence interval intersects with the reference line, the predicted risk in that decile is not significantly different from the observed risk. If the confidence interval of a decile deviates from the reference line, there is a suggestion of either overprediction (below the line) or underprediction (above the line) of EOC risks by the BOADICEA model. Null age-only model, PRS polygenic risk scores, PV pathogenic variants, QRF questionnaire-based risk factors, FH family history.
Fig. 2
Fig. 2. Observed and predicted 10-year EOC risks by age under the full model.
a Age <60 (N = 110,885); b age ≥60 (N = 88,544). Women were grouped into deciles based on their predicted risks. Each dot represents the mean observed and predicted risk in the decile and error bar represents the 95% confidence intervals.
Fig. 3
Fig. 3. Observed and predicted 10-year EOC risks in pathogenic variant carriers (N = 1231) under the model considering PV only, PV + PRS + QRF and PV + PRS + QRF + FH.
Women were grouped into deciles based on their predicted risks. Each dot represents the mean observed and predicted risk in the decile, and the error bar represents the 95% CIs.

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015;136:E359–86. - PubMed
    1. Cancer Research UK. Ovarian cance survival2016-2020. Available from: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/survival.
    1. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93:937–44. - PubMed
    1. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151–6. - PubMed
    1. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182–93. - PMC - PubMed

Publication types

MeSH terms